Showing 4931-4940 of 6036 results for "".
- Computer Model Fosters Potential Improvements to ‘Bionic Eye’ Technologyhttps://modernod.com/news/computer-model-fosters-potential-improvements-to-bionic-eye-technology/2479063/There are millions of people who face the loss of their eyesight from degenerative eye diseases. The genetic disorder retinitis pigmentosa alone affects 1 in 4,000 people worldwide. Today, there is technology available to offer partial eyesight to people with that syndrome. The Argus II, the worl
- LumiThera Announces Topline Data in the European Multicenter LIGHTSITE II Study to Treat Dry AMDhttps://modernod.com/news/lumithera-announces-topline-data-in-the-european-multicenter-lightsite-ii-study-to-treat-dry-amd/2479059/LumiThera announced positive findings in its LIGHTSITE II multicenter clinical trial in dry age-related macular degeneration (AMD) patients. The prospective, double-masked, randomized, multicenter, European Union post-marketing clinical trial, titled LIGHTSITE II, was conducted in eight re
- Systematic Review of Standalone iStent Trabecular Micro-Bypass Glaucoma Surgeryhttps://modernod.com/news/systematic-review-of-standalone-istent-trabecular-micro-bypass-glaucoma-surgery/2479056/A new meta-analysis of the iStent and iStent inject (Glaukos) found that standalone trabecular micro-bypass glaucoma surgery with the devices is associated with clinically relevant reductions in intraocular pressure. The focus of the study, which was published in the Journal of Glaucom
- OneSight Partners With Anthem Blue Cross and Blue Shield Foundation to Provide Free Eye Exams and Glasses in Cincinnatihttps://modernod.com/news/onesight-partners-with-anthem-blue-cross-and-blue-shield-foundation-to-provide-free-eye-exams-and-glasses-in-cincinnati/2479049/Preventative care visits have dropped significantly over the course of the pandemic, and this is especially true in under-served communities. That’s why the Anthem Blue Cross and Blue Shield Foundation teamed up with OneSight, a leading global vision care nonprofit, to provide free eye exams and
- Infectious Disease Researcher Appointed Inaugural Chief Scientific Officer at Mass Eye and Earhttps://modernod.com/news/infectious-disease-researcher-appointed-inaugural-chief-scientific-officer-at-mass-eye-and-ear/2479047/Michael S. Gilmore, PhD, a microbiologist who has led infectious disease efforts at leading research institutions, has been appointed the first Chief Scientific Officer at Mass Eye and Ear. Dr. Gilmore will assume the role on May 1, 2021. He has served as Director of the Infectious Disease
- COVID-19 Accelerates Trend of Hospitals Acquiring Ambulatory Surgery Centershttps://modernod.com/news/covid-19-accelerates-trend-of-hospitals-acquiring-ambulatory-surgery-centers/2479048/The pandemic has accelerated a growing desire among providers and even some medical technology manufacturers to acquire or get into the surgery center business, experts say, according to a Fierce Healthcare
- Johnson & Johnson Begins Testing COVID-19 Vaccine in Adolescentshttps://modernod.com/news/johnson-johnson-begins-testing-covid-19-vaccine-in-adolescents/2479045/Johnson & Johnson announced that it has begun vaccinating adolescent participants in an ongoing phase 2a trial of its COVID-19 vaccine candidate Ad26.COV2.S. The study, which got under way last September, was initially designed to evaluate single- and two-dose regimens of the vaccine in healt
- Eyenovia Announces Appointment of Julia Haller, MD, to its Board of Directorshttps://modernod.com/news/eyenovia-announces-appointment-of-julia-haller-md-to-its-board-of-directors/2479041/Eyenovia announced the appointment of Julia Haller, MD, to its Board of Directors. “We are delighted to welcome Dr. Haller to our Board of Directors at such an exciting time for Eyenovia,” Sean Ianchulev, MD, PhD, Chief Executive Officer and Chief Medical
- Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Study for Lytenavahttps://modernod.com/news/outlook-therapeutics-reports-positive-safety-profile-from-norse-three-study-for-lytenava/2479037/Outlook Therapeutics announced positive topline results from its NORSE THREE open-label safety study evaluating ONS-5010/Lytenava (bevacizumab-vikg) to treat retinal diseases. Topline results from the open-label safety study demonstrated that ONS-5010 showed no unexpecte
- Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of Concept Agreement for Two Ophthalmic Drug Candidateshttps://modernod.com/news/nanoform-and-nacuity-pharmaceuticals-sign-technology-proof-of-concept-agreement-for-two-ophthalmic-drug-candidates/2479035/Nanoform Finland and Nacuity Pharmaceuticals announced that they have signed a Technology Proof of Concept Agreement, with compensation on standard commercial terms. This will apply Nanoform’s nanoparticle CESS technology to enhance ophthalmic drug delivery of Nacuity’s NPI-001 and N